Healthcare & Life Sciences

Starnatx

series-b
series-b
Stage
1
Investors

About

Starnatx develops liver-extrinsic targeted lipid nanoparticle (LNP) delivery systems to advance RNA-based innovative therapeutics, including in vivo cell therapies and vaccines.

Explore Starnatx's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.